CVKD - CIK 0001937993
The table below shows Cadrenal Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $771.51K | $688.47K | $1.08M | $1.67M | $784.65K | $1.25M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.74M |
| $2.04M |
| $2.66M |
| $2.25M |
| $1.67M |
| $1.21M |
| Operating income | -$2.51M | -$2.73M | -$3.73M | -$3.93M | -$2.46M | -$2.47M |
| Income tax | - | - | - | - | - | - |
| Net income | -$2.50M | -$2.69M | -$3.67M | -$3.85M | -$2.41M | -$2.39M |
| EPS (diluted) | -$1.04 | -$1.31 | -$1.87 | -$2.09 | -$2.18 | -$2.24 |